COVID-19 Vaccine Research Study
Researchers at Trialmed are conducting a study on the Pfizer COVID-19 vaccine for generally healthy adults ages 50–64.
Fast Facts
No COVID-19 Infection or Vaccine in the Last 90 Days
50-64 Years Old
Compensation
Provided Up To $1,125
Conducted in
Birmingham, AL
Study Background
This research study is evaluating how well the Pfizer COVID-19 vaccine helps protect healthy adults ages 50–64 against COVID-19.
COVID-19 continues to impact communities across the country, and ongoing research helps scientists better understand how vaccines work in different populations. While vaccines are widely available, studies are still important to evaluate immune response and long-term protection in specific age groups.
This study will monitor participants over a period of at least six months to assess protection against COVID-19 and evaluate immune response in some participants through optional blood samples. Information gathered may help inform future vaccine recommendations and public health decisions.
Study Background
This research study is evaluating how well the Pfizer COVID-19 vaccine helps protect healthy adults ages 50–64 against COVID-19.
COVID-19 continues to impact communities across the country, and ongoing research helps scientists better understand how vaccines work in different populations. While vaccines are widely available, studies are still important to evaluate immune response and long-term protection in specific age groups.
This study will monitor participants over a period of at least six months to assess protection against COVID-19 and evaluate immune response in some participants through optional blood samples. Information gathered may help inform future vaccine recommendations and public health decisions.
Additional Information
This study is being conducted to better understand how well the Pfizer COVID-19 vaccine helps protect healthy adults ages 50–64 from COVID-19 infection.
You may be eligible for this study if you are 50-64 years old and meet the following criteria:
Inclusion Criteria:
- No COVID-19 infection or vaccine in the last 90 days
- No asthma, chronic obstructive pulmonary disease (COPD), diabetes, current or former smokers, or cardiovascular/cerebrovascular disease (including heart failure, heart attack, stroke, coronary artery disease, stents, or myocarditis/pericarditis)
- No medical condition that increases the risk of severe COVID-19
- No obesity
If you choose to participate:
Step 1: Phone Screening
You will complete a phone interview to determine if you qualify.Step 2: Vaccination Visit (Visit 1)
You will visit the research site to receive the study vaccine.Step 3: 1-Month Follow-Up (Visit 3)
You will return to the research site approximately one month later for follow-up.Additional Visits (Some Participants)
Some participants will return at 3 months and 6 months after vaccination to provide blood samples to evaluate immune response.
Others may complete these visits by phone.Health Monitoring
You may be asked to attend additional visits if you experience symptoms suggestive of COVID-19 or certain heart-related symptoms, or if the study physician would like to evaluate changes in your health.
Participants will be in the study for at least 6 months, or longer, depending on the illness monitoring period.
5 Site locations:
Birmingham, AL, Melbourne, FL, The Villages, FL, Tucson, AZ, Phoenix, AZ
Participants may receive up to $1,125 for time and participation. Transportation assistance may be available if needed
There is no cost for you to participate in our research study.